Search - tctmd.com

Displaying 1 - 20 of 132

Sort: Relevancy | Date

Year in Review: Physicians Pick the Biggest News of 2017, in Interventional Cardiology and Beyond

News Daily News

Year in Review: Physicians Pick the Biggest News of 2017, in Interventional Cardiology and Beyond

December 26, 2017

AAFP Says It Cannot Endorse New Hypertension Guideline

News Daily News

AAFP Says It Cannot Endorse New Hypertension Guideline

December 18, 2017

Gap in Industry Payments to Women vs Men Seen Across Medical Specialties

News Daily News

Gap in Industry Payments to Women vs Men Seen Across Medical Specialties

December 18, 2017

Some Concerns About New ‘Tour de Force’ Hypertension Guidelines

News Daily News

Some Concerns About New ‘Tour de Force’ Hypertension Guidelines

December 04, 2017

More Support for TMVR After Failed Mitral Bioprostheses

News Conference News AHA 2017

More Support for TMVR After Failed Mitral Bioprostheses

Yael L. Maxwell

November 23, 2017

My Takeaways From TCT 2017: Show Up, Keep It Civil, and Bring Your Best Self

News Opinion Editor's Corner TCT 2017

My Takeaways From TCT 2017: Show Up, Keep It Civil, and Bring Your Best Self

November 22, 2017

Long-Awaited Hypertension Guidelines Released at AHA

News Conference News AHA 2017

Long-Awaited Hypertension Guidelines Released at AHA

November 13, 2017

Experts Debate: Should Cerebral Protection Be Used for All TAVRs?

News Conference News TCT 2017

Experts Debate: Should Cerebral Protection Be Used for All TAVRs?

November 09, 2017

A-fib Signals Worse Prognosis After Aortic Valve Replacement in Intermediate-Risk Patients

News Conference News TCT 2017

A-fib Signals Worse Prognosis After Aortic Valve Replacement in Intermediate-Risk Patients

November 08, 2017

Hemodynamic Trends on Serial Echocardiograms after TAVR: Comprehensive 5-Year Analyses From PARTNER

Presentation TCT 2017

Hemodynamic Trends on Serial Echocardiograms after TAVR: Comprehensive 5-Year Analyses From PARTNER

Presenter: Pamela S. Douglas

November 01, 2017

TCT 8391: Atrial Fibrillation Is Associated With Increased Mortality in Intermediate-Risk Patients Undergoing TAVR or SAVR - Insights From the PARTNER 2A and PARTNER 2 S3i Trials

Presentation TCT 2017

TCT 8391: Atrial Fibrillation Is Associated With Increased Mortality in Intermediate-Risk Patients Undergoing TAVR or SAVR - Insights From the PARTNER 2A and PARTNER 2 S3i Trials

Presenter: Steven R. Bailey, Patrick W. Serruys, Angelo Biviano, MD

November 01, 2017

Intermediate-Risk TAVR Substantially More Cost-effective Than Surgery

News Conference News TCT 2017

Intermediate-Risk TAVR Substantially More Cost-effective Than Surgery

Yael L. Maxwell

October 31, 2017

TCT 51: Impact of Anticoagulation Therapy on Valve Hemodynamics and Clinical Outcomes After Bioprosthetic Aortic Valve Replacement: A Pooled Analysis of the PARTNER2 Trials

Presentation TCT 2017

TCT 51: Impact of Anticoagulation Therapy on Valve Hemodynamics and Clinical Outcomes After Bioprosthetic Aortic Valve Replacement: A Pooled Analysis of the PARTNER2 Trials

Presenter: Peter C. Block, Lars Sondergaard, Tarun Chakravarty, MD

October 31, 2017

PARTNER 2A and SAPIEN 3 Cost-effectiveness: Cost-effectiveness of TAVR vs SAVR in Intermediate-Risk Patients With Aortic Stenosis

Presentation TCT 2017

PARTNER 2A and SAPIEN 3 Cost-effectiveness: Cost-effectiveness of TAVR vs SAVR in Intermediate-Risk Patients With Aortic Stenosis

Presenter: Patrick W. Serruys, David J. Cohen

October 31, 2017

Live From Denver: TCT 2017, Day Two

News Conference News TCT 2017

Live From Denver: TCT 2017, Day Two

October 31, 2017

Important Clinical Lessons From the VIVID Registry and the PARTNER Experience

Presentation TCT 2017

Important Clinical Lessons From the VIVID Registry and the PARTNER Experience

Presenter: John G. Webb

October 30, 2017

The PARTNER 3 Low-risk Trial

Presentation TCT 2017

The PARTNER 3 Low-risk Trial

Presenter: Michael J. Mack

October 30, 2017

Viewpoint #1: PARTNER 2A and SURTAVI are Convincing – TAVR is Preferred in ALL (Appropriate) Intermediate-Risk Patients

Presentation TCT 2017

Viewpoint #1: PARTNER 2A and SURTAVI are Convincing TAVR is Preferred in ALL (Appropriate) Intermediate-Risk Patients

Presenter: Michael J. Reardon

October 30, 2017

News Opinion Off Script TCT 2017

Off Script: Welcome to TCT 2017 in the Mile High City

October 29, 2017

Take-home Messages and Closing Comments

Presentation TCT 2017

Take-home Messages and Closing Comments

Presenter: Amal Kumar Banerjee, Rabin dra Nath Chakraborty

October 29, 2017

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.